Spinal meningiomas account for 1.2–12% of all meningiomas and 25–45% of all spinal tumors. About 20% of intracranial meningiomas and 4.6% of spinal meningiomas recur and require additional treatment. The classification of intracranial meningiomas has evolved considerably in recent years and uses genetic [1, 3, 7] as well as epigenetic parameters [5, 8] in order to more precisely predict the patients’ prognosis and to lay the ground for therapeutic regimens that are adapted to the aggressiveness of a patient’s tumor. Spinal meningiomas are missing in many of the large cohorts that were gathered for molecular profiling of meningiomas and have neither been thoroughly analyzed separately. Therefore, their classification still relies mostly on histopathological findings.
We performed genetic and epigenetic profiling of 65 tumor samples from patients with histologically proven spinal meningioma. Clinical features are described in Supplementary Table 1, online resource, and raw data are accessible at GEO under GSE212449. T-distributed Stochastic Neighbor Embedding (t-SNE) analysis of genome-wide DNA methylation data shows that most spinal meningiomas separated from cranial meningiomas and formed two distinct clusters (Fig. 1a, b). Sixteen out of 19 cases in cluster 1 (84%) significantly matched the methylation class “benign-2” [8], while cluster 2 was more heterogeneous with only 5/42 samples reaching a significant match (12%, MSC score > 0.9, Fig. 1c and d, Supplementary Fig. 1a–c, online resource). Of 19 meningiomas in cluster 1, 13 (68%) were of the meningothelial subtype, 12 (63%) occurred in the cervical spine, and 13 (68%) occurred in male patients (Chi-square, p < 0.001, Fig. 1d, Supplementary Fig. 1d–i, online resource). Notably, all cases with verified AKT1 E17K mutations resided in cluster 1, thereby making up the majority of this cluster (8/13 cases analyzed for mutations). NF2 mutations were detected in 24/32 spinal meningiomas (75%) of the second cluster (Supplementary Fig. 1j, online resource), but only in a single tumor in cluster 1. In line with this observation, a hemizygous loss of chromosome 22q was observed in most cluster 2 cases (29/32, 91%), but only in 3/19 cluster 1 cases (16%, p < 0.0001, Fig. 1d and e). Other mutations that may occur in meningiomas [6] were not recurrently found in our cohort (Supplementary Table 1, online resource). Seven spinal tumors showed close association with cranial meningioma of intermediate and malignant methylation subclasses according to t-SNE analysis (Fig. 1b) and did not show a clear association with cluster 1 or 2 in this context. These cases had a particularly high frequency of cytogenetic aberrations (Fig. 1d and e, marked by asterisks). Collectively, these data suggest that spinal meningiomas encompass two major clinically, genetically, and epigenetically distinct tumor groups, which are either localized primarily in the cervical or the thoracic spine. These data are well in line with recently published work [4] and further complement this work by extensive epigenetic characterization of such tumors. Together, such results may, in the end, lead to a more precise and clinically relevant classification of spinal meningiomas.
Supplementary Information
Below is the link to the electronic supplementary material.
Acknowledgements
We thank Nicole Borgardt and Helena Gladkov (Hamburg) for technical support.
Funding
Open Access funding enabled and organized by Projekt DEAL. Deutsche Krebshilfe, 70112956, Franz Ricklefs, Fördergemeinschaft Kinderkrebs-Zentrum Hamburg. F.L.R. received funding from the German Society of Neurosurgery (DGNC) and Eurospine; F.L.R., F.S., K.L., and M.W. received funding by the German Cancer Aid (grant number 70112956). K.F. receives funding from the Forschungsförderungsfond der Medizinischen Fakultät (UKE Hamburg), and U.S. receives funding from the Fördergemeinschaft Kinderkrebszentrum Hamburg.
Declarations
Conflict of interest
The authors declare no conflict of interest.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Franz L. Ricklefs and Krystian D. Fita are shared first authors. Ulrich Schüller and Sven O. Eicker are shared senior authors.
Contributor Information
Ulrich Schüller, Email: u.schueller@uke.de.
Sven O. Eicker, Email: s.eicker@uke.de
References
- 1.Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013;45:285–289. doi: 10.1038/ng.2526. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555:469–474. doi: 10.1038/nature26000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339:1077–1080. doi: 10.1126/science.1233009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Hua L, Alkhatib M, Podlesek D, Günther L, Pinzer T, Meinhardt M, et al. Two predominant molecular subtypes of spinal meningioma: thoracic NF2-mutant tumors strongly associated with female sex, and cervical AKT1-mutant tumors originating ventral to the spinal cord. Acta Neuropathol. 2022 doi: 10.1007/s00401-022-02474-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Maas SLN, Stichel D, Hielscher T, Sievers P, Berghoff AS, Schrimpf D, et al. Integrated molecular-morphologic meningioma classification: a multicenter retrospective analysis, retrospectively and prospectively validated. J Clin Oncol. 2021;39:3839–3852. doi: 10.1200/JCO.21.00784. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Mawrin C, Koch R, Waldt N, Sandalcioglu IE, Braunsdorf WEK, Warnke JP, et al. A new amplicon-based gene panel for next generation sequencing characterization of meningiomas. Brain Pathol. 2022;32:e13046. doi: 10.1111/bpa.13046. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Sahm F, Schrimpf D, Olar A, Koelsche C, Reuss D, Bissel J, et al. TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst. 2016 doi: 10.1093/jnci/djv377. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 2017;18:682–694. doi: 10.1016/S1470-2045(17)30155-9. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.